<DOC>
	<DOC>NCT03076112</DOC>
	<brief_summary>The objectives of this study are 1) to compare the effect of ipragliflozin 50 mg on glucose-lowering effect with sitagliptin 100 mg in patients with type 2 diabetes mellitus, whose HbA1c level is ≥ 7.5% with sulfonylurea and metformin, 2) to investigate changes of other metabolic and cardiovascular risk factors such as triglyceride, HDL-cholesterol, uric acid, blood pressure, and inflammatory markers, 3) to examine changes of body composition including fat and muscle mass with volume status.</brief_summary>
	<brief_title>Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Type 2 diabetes with HbA1c 7.5% 9.0% at screening visit Male or female between 20 and 75 years of age Patients taking sulfonylurea (glimepiride 1~8mg or gliclazide 30~120 mg or equivalent dose) and metformin (≥ 1000 mg or maximum tolerated dose) for more than 3 months BMI ≥23 kg/m² Estimated GFR ≥ 60 ml/min/1.73m² Women of child bearing potential must take precautions to avoid pregnancy throughout the study and for 4 weeks after intake of the last dose and must have a negative urinary pregnancy test. Type 1 diabetes, gestational diabetes, or diabetes with secondary cause Patients with acute coronary syndrome within 3 months prior to screening visit Patients with acute coronary syndrome within 3 months prior to screening visit Pregnant or breastfeeding women or reproductiveage women who refuse contraception Chronic hepatitis B or C (except healthy carrier of HBV), liver disease (AST/ALT &gt; 3fold the upper limit of normal) Cancer within 5 years (except squamous cell cancer, cervical cancer, thyroid cancer with appropriate treatment) except thyroid cancer or carcinoma in situ Other clinical trials within 30 days Alcohol abuse Contraindication to SGLT2 inhibitors or Dipeptidylpeptidase 4 inhibitors Taking insulin, oral hypoglycemic agents other than metformin, sulfonylurea, and the study drugs.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Ipragliflozin</keyword>
	<keyword>Sitagliptin</keyword>
</DOC>